ClinicalTrials.gg
RecruitingNCT06890078OPTIJIROVECUpdated Apr 23, 2026

Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients

An observational study in Pneumocystis and Immunocompromised Patients, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 4 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Pneumonia, Pneumocystis with a site in France — 3 open to participants now, 4 under way, none of them phase 3. Pneumonia, Pneumocystis · France.

Started
2025
with 1 other
Observational
8 of 15
2 open now
Registered
14th of 15
by date
Lead sponsor
2 of 15
Assistance Publique - Hôpitaux de Paris

Among the 15 studies in Pneumonia, Pneumocystis with a site in France, this one is one of 2 that started in 2025, is one of 8 observational ones, and was the 14th registered.

Pneumonia, Pneumocystis

108 studies on the registry are indexed under Pneumonia, Pneumocystis; 16 are open to participants now.

Browse Pneumonia, Pneumocystis studies →

Open to participants now

3 of the 15 studies in Pneumonia, Pneumocystis with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 9 Pneumonia, Pneumocystis studies recruiting now, 6 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pneumonia, Pneumocystis with a site in France, or all of them as a file.
02

Study summary

Evaluate new diagnostic methods using qPCR on non-invasive samples, compared with reference techniques for the positive diagnosis of pneumocystis (PcP) in immunocompromised patients

03

Conditions studied

  • Pneumocystis
  • Immunocompromised Patients

Keywords

  • immunocompromised patients
  • pneumocystis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adult patients with suspected pneumocystis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients with suspected pneumocystis
  • with an indication for bronchial fibroscopy for BAL or induced sputum
  • no opposition to the research from the adult patient or his or her next of kin research for patients unable to express their non-opposition

Exclusion criteria

Exclusion Criteria:

  • Pneumocystis treated for more than 72 hours
  • pregnancy/breast-feeding
  • adult patients deprived of liberty, protected
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Adults with suspicion of pneumocystis

    Other: Biological sampling

Interventions

  • OtherBiological sampling

    Mouthwash, nasopharyngeal swab, blood sampling

06

What researchers measure

Primary outcomes

  1. Pearson correlation coefficient

    Pearson correlation coefficient between the fungal load obtained by PCR on nasopharyngeal swabs nasopharyngeal swab and buccal lavage and that obtained by reference samples (induced sputum or BAL) in patients with confirmed PcP.

    Time frame: At inclusion

Secondary outcomes

  1. Fungal load by qPCR

    Quantitative fungal load results obtained by qPCR on nasopharyngeal swab, mouthwash, induced sputum, BAL

    Time frame: At inclusion

  2. Fungal load by serum PCR

    Quantitative fungal load results obtained by serum PCR

    Time frame: At inclusion

  3. Beta D glucan blood levels

    Time frame: At inclusion

07

Study locations

4 of 4 sites recruiting
  • Hôpital Lariboisière AP-HP Maladies infectieuses
    Paris, France
    Recruiting
  • Hôpital Saint Louis AP-HP Maladies infectieuses
    Paris, France
    Recruiting
  • Hôpital Saint Louis AP-HP Réanimation
    Paris, France
    Recruiting
  • Hôpital Saint-Louis AP-HP Pneumologie
    Paris, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Mar 21, 2025
StartActual
Jul 8, 2025
Primary completionEst.
Jul 8, 2027
CompletionEst.
Jul 8, 2027
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06890078
Responsible party
Sponsor
First posted
Mar 21, 2025
Start date
Jul 8, 2025
Primary completion
Jul 8, 2027 (estimated)
Completion
Jul 8, 2027 (estimated)
Last update
Apr 23, 2026

Study contacts

Agathe Vigouroux, MD
Contact
agathelaure.vigouroux@aphp.fr
0142494683 ext. +33
Jérôme Lambert, MD PhD
Contact
jerome.lambert@u-paris.fr
+33 1 42 49 97 42 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion